Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells

OncoImmunology

Volumn 7, Issue 1, 2018, Pages

  Shime, Hiroaki ^a,b   Maruyama, Akira ^a   Yoshida, Sumito ^a   Takeda, Yohei ^a   Matsumoto, Misako ^a   Seya, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Inducible NO synthase (iNOS NOS2); interferon (IFN ); macrophages; monocytic MDSCs (M MDSCs); myeloid derived suppressor cells (MDSCs); nitric oxide (NO); toll like receptor 2 (TLR2)

Indexed keywords

EID: 85029697694     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1373231     Document Type: Article

References (43)

1. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014-22. doi:10.1038/ni.2703. PMID:24048123
2. Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16:447-62. doi:10.1038/nrc.2016.54. PMID:27339708
3. Seya T, Shime H, Matsumoto M. Functional Alteration of Tumor-infiltrating Myeloid Cells in RNA Adjuvant Therapy. Anticancer Res. 2015;35:4385-92. PMID:26168476
4. Akazawa T, Inoue N, Shime H, Kodama K, Matsumoto M, Seya T. Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Sci. 2010;101:1596-603. doi:10.1111/j.1349-7006.2010.01583.x. PMID:20507323
5. Sawahata R, Shime H, Yamazaki S, Inoue N, Akazawa T, Fujimoto Y, Fukase K, Matsumoto M, Seya T. Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011;13:350-8. doi:10.1016/j.micinf.2010.12.003. PMID:21172450
6. Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer–focusing on TLR2 and TLR3 agonists for safely enhancing antitumor immunity. Cancer Sci. 2015;106:1659-68. doi:10.1111/cas.12824. PMID:26395101
7. Shen K-Y, Song Y-C, Chen I-H, Leng C-H, Chen H-W, Li H-J, Chong P, Liu S-J. Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol. 2014;192:4233-41. doi:10.4049/jimmunol.1302850. PMID:24683188
8. Azuma M, Sawahata R, Akao Y, Ebihara T, Yamazaki S, Matsumoto M, Hashimoto M, Fukase K, Fujimoto Y, Seya T. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS ONE. 2010;5(9):e12550. doi:10.1371/journal.pone.0012550. PMID:20824059
9. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa T-O, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22:466-78. doi:10.1016/j.ccr.2012.08.010. PMID:23079657
10. Kim S, Takahashi H, Lin W-W, Descargues P, Grivennikov S, Kim Y, Luo J-L, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102-6. doi:10.1038/nature07623. PMID:19122641
11. Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS ONE. 2011;6:e18833. doi:10.1371/journal.pone.0018833. PMID:21533081
12. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356-64. doi:10.1172/JCI80005. PMID:26168215
13. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181:5791-802. doi:10.4049/jimmunol.181.8.5791. PMID:18832739
14. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91:167-81. doi:10.1189/jlb.0311177. PMID:21954284
15. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168:689-95. doi:10.4049/jimmunol.168.2.689. PMID:11777962
16. Raber PL, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez ME, Ochoa AC, Fletcher M, Velasco C, Wilk A, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2014;134:2853-64. doi:10.1002/ijc.28622. PMID:24259296
17. Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen K-M, Guenova E, Demircioglu D, Kempf WE, Volz T, et al. Cutaneous Innate Immune Sensing of Toll-like Receptor 2–6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells. Immunity. 2014;41:762-75. doi:10.1016/j.immuni.2014.10.009. PMID:25456159
18. Maruyama A, Shime H, Takeda Y, Azuma M, Matsumoto M, Seya T. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochem Biophys Res Commun. 2015;457:445-50. doi:10.1016/j.bbrc.2015.01.011. PMID:25596131
19. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin J-P, Boireau W, Rouleau A, Simon B, Lanneau D, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120:457-71. PMID:20093776
20. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE, Graeber TG, Sieling PA, Liu Y-J, Rea TH, et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med. 2005;11:653-60. doi:10.1038/nm1246. PMID:15880118
21. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol. 1998;160:5729-34. PMID:9637481
22. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N, Seya T. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA. 2012;109:2066-71. doi:10.1073/pnas.1113099109. PMID:22308357
23. Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M, Seya T. Myeloid-Derived Suppressor Cells Confer Tumor-Suppressive Functions on Natural Killer Cells via Polyinosinic:Polycytidylic Acid Treatment in Mouse Tumor Models. J Innate Immun. 2014;6:293-305. doi:10.1159/000355126. PMID:24192491
24. Shime H, Matsumoto M, Seya T. Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b(+)Ly6G(+) intratumor myeloid cells through the TICAM-1 signaling pathway. Cell Death Differ. 2017;24:385-96. doi:10.1038/cdd.2016.131. PMID:27834952
25. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880-91. doi:10.4049/jimmunol.174.8.4880. PMID:15814715
26. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J-I, Cheng P, Cho H-I, Celis E, Quiceno DG, Padhya T, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207:2439-53. doi:10.1084/jem.20100587. PMID:20876310
27. Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G, Penman E, et al. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity. 2016;44:303-15. doi:10.1016/j.immuni.2016.01.014. PMID:26885857
28. Hanke NT, LaCasse CJ, Larmonier CB, Alizadeh D, Trad M, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15. Eur J Immunol. 2014;44:2489-99. doi:10.1002/eji.201343803. PMID:24777831
29. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol. 2016;37:208-20. doi:10.1016/j.it.2016.01.004. PMID:26858199
30. Nagaraj S, Schrum AG, Cho H-I, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106-16. doi:10.4049/jimmunol.0902661. PMID:20142361
31. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181:4666-75. doi:10.4049/jimmunol.181.7.4666. PMID:18802069
32. Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:2235-49. doi:10.1084/jem.20080132. PMID:18809714
33. Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res. 2011;17:1765-75. doi:10.1158/1078-0432.CCR-10-2672. PMID:21233400
34. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol. 2012;188:1592-9. doi:10.4049/jimmunol.1101304. PMID:22231700
35. Lee M, Park C-S, Lee Y-R, Im S-A, Song S, Lee C-K. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37:1234-40. doi:10.1007/s12272-014-0379-4. PMID:24748512
36. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunol. 2014;3:e29179. doi:10.4161/onci.29179.
37. Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunol. 2015;4:e974411-4. doi:10.4161/2162402X.2014.974411.
38. Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunol. 2015;4:e954829-11. doi:10.4161/21624011.2014.954829.
39. Akazawa T, Ohashi T, Nakajima H, Nishizawa Y, Kodama K, Sugiura K, Inaba T, Inoue N. Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation. Int J Cancer. 2014;135:2847-56. doi:10.1002/ijc.28939. PMID:24789268
40. Geisel J, Kahl F, Müller M, Wagner H, Kirschning CJ, Autenrieth IB, Frick J-S. IL-6 and maturation govern TLR2 and TLR4 induced TLR agonist tolerance and cross-tolerance in dendritic cells. J Immunol. 2007;179:5811-8. doi:10.4049/jimmunol.179.9.5811. PMID:17947654
41. Tang M, Diao J, Gu H, Khatri I, Zhao J, Cattral MS. Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling. Cell Rep. 2015;13:2851-64. doi:10.1016/j.celrep.2015.11.053. PMID:26711349
42. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell. 2016;29:587-601. doi:10.1016/j.ccell.2016.03.005. PMID:27070705
43. Yokouchi H, Chamoto K, Wakita D, Yamazaki K, Shirato H, Takeshima T, Dosaka-Akita H, Nishimura M, Yue Z, Kitamura H, et al. Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma. Clin Exp Metastasis. 2007;24:533-40. doi:10.1007/s10585-007-9090-x. PMID:17653821